Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Hoth Therapeutics, Inc. (HOTH)
|
Add to portfolio |
|
|
|
| Price: |
$1.30
| | Metrics |
| OS: |
3.3
|
M
| |
|
|
| Market cap: |
$4.29
|
M
| |
|
|
|
Net cash:
|
$11.6
|
M
| |
$3.51
|
per share
|
|
EV:
|
|
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($11.4)
|
M
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 |
| Revenues | 65.3 | 0.0 | 0.0 | 2.9 | 0.5 |
| Revenue growth | -156195.3% | 3452.1% | -100.0% | 475.5% | |
| Cost of goods sold | 2.6 | -3.0 | -1.5 | 2.9 | 0.5 |
| Gross profit | 62.7 | 3.0 | 1.5 | 0.0 | 0.0 |
| Gross margin | 96.0% | -7161.8% | -123475.0% | 0.0% | 0.0% |
| Selling, general and administrative | 3.5 | 3.5 | | | |
| Research and development | 4.8 | 7.4 | 2.3 | 2.0 | 0.8 |
| General and administrative | 2.6 | 2.8 | 2.5 | 2.1 | 0.7 |
| EBIT | -11.4 | -14.1 | -7.3 | -7.7 | -2.5 |
| EBIT margin | -17.5% | 33729.0% | 620388.6% | -263.0% | -489.6% |
| Pre-tax income | -11.4 | -14.3 | -7.2 | -7.7 | -2.5 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -11.4 | -14.3 | -7.2 | -7.7 | -2.5 |
| Net margin | -17.4% | 34158.0% | 611539.2% | -262.7% | -489.6% |
| |
| Diluted EPS | ($9.50) | ($15.99) | ($0.58) | ($0.84) | ($0.50) |
| Shares outstanding (diluted) | 1.2 | 0.9 | 12.4 | 9.2 | 5.0 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|